Pfizer Inc.
Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body

Last updated:

Abstract:

Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.

Status:
Grant
Type:

Utility

Filling date:

12 May 2016

Issue date:

16 Mar 2021